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We thank Dr Caro et al. for their reﬂections. It was not
the purpose of our article to suggest that decision
models based on patient-level simulations (PLS) were
inappropriate. On the contrary, we accept that there
may well be situations where the speciﬁcs of disease
prognosis and treatment effects will necessitate such an
approach.
The key feature of any decision model, however, is
to be “ﬁt for purpose” for decision-making. That is,
such models need to generate estimates of the expected
cost-effectiveness, decision uncertainty associated with
each option and the cost of uncertainty, and hence
potential value of further research [1]. We are
impressed that Caro et al. ﬁnd the computational task
associated with generating these required outputs a
trivial task in PLS models. As evidenced by our review,
others have not found this quite so straightforward:
only one out of six PLS models included in technology
assessments for the National Institute for Health and
Clinical Excellence in the UK conducted probabilistic
analysis compared with 16 out of 24 cohort models
[2]. This is probably not surprising in PLS models with
the levels of complexity apparently advocated in most
situations by Caro et al. Such models may require
10,000 individual simulations to provide a single
stable estimate of expected cost-effectiveness—Caro
et al.’s implication of 1000 patients in a complex
model seems low. A further level of 10,000 draws from
parameter distributions to reﬂect decision uncertainty
(i.e., 10,000 ¥ 10,000 = 100,000,000 simulations).
Further levels of simulation would be required fully to
evaluate the value of perfect information in general
and for individual parameters. For most modelers, this
is far from a trivial undertaking. If Caro et al. have
innovative methods (other than emulators such as the
use of a Gaussian process [3], which they seem to
disparage) to speed the process up, it would be of
beneﬁt to the modeling community for these to be
published.
It is important to remember that all models are
seeking to approximate reality rather than replicate
it—“all models are wrong, but some are useful” in
George Box’s words [4]. Of course, this is as true with
decision models based on PLS as any other—if that
were not the case, then why do such analyses stop at
the level of individual patients rather than modeling at
the organ system, cellular, molecular, or even atomic
level! Given the nature of the decision problem the
model is seeking to inform, judgments always have to
be taken regarding the appropriateness of simplifying
assumptions. We would argue that the parameteriza-
tion and computational burden of PLS compared with
cohort models suggests that analysts should carefully
assess whether these additional costs can be justiﬁed in
terms of their impact on the ultimate decision. We
believe that most of the features of a disease which
Caro et al. feel necessitate the use of PLS can be appro-
priately handled in cohort models. There may be a
limit to this, and PLS may be deemed necessary to
reﬂect the complexities of a disease process, but ana-
lysts cannot avoid the need to quantify decision uncer-
tainty and value of information, the omission of which
most PLS modelers in our review were guilty.
We ﬁnd little to disagree with Caro et al.’s closing
comment that models need to be as realistic as neces-
sary to inform decisions. However, there is no reason
why this should imply PLS in each and every
case.—Susan Grifﬁn, Karl Claxton, Neil Hawkins, and
Mark Sculpher, University of York, York, UK.
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